#$%^&*AU2017201628A120170330.pdf#####ABSTRACT The invention relates to methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) in patients scheduled to undergo treatment with nitric oxide inhalation, by excluding patients who have preexisting left ventricular dysfunction.